According to a new analysis published in the European Journal of Cancer, researchers have found that second-line nintedanib plus docetaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC) improves overall survival without decreasing quality of life.
In the double-blind, placebo-controlled, phase 3 LUME-Lung 1 study, researchers found that the combination of nintedanib with docetaxel significantly improved overall survival when used as second-line treatment for patients with advanced NSCLC and adenocarcinoma histology.
Now, researchers assessed whether the combination therapy affected patient-reported outcomes for symptoms and health-related quality of life. Patients were asked about their symptoms at screening, on the first day of each cycle, at the end of chemotherapy, and at the first follow-up appointment.
Results showed that there was no significant difference in time to deterioration of quality of life or lung cancer-specific symptoms, such as cough, dyspena, and pain, between both arms.
The difference was similar for both the overall population and those with adenocarcinoma. However, the time to deterioration of certain gastrointestinal symptoms was shorter in the nintedanib arm compared with the placebo arm. There was also no significant difference in the EuroQol disease-generic questionnaire between the two treatment arms.
Patient-reported outcomes (PROs) for symptoms and health-related quality of life (QoL) are reported here. The significant overall survival (OS) benefit observed with the addition of nintedanib to docetaxel therapy was achieved with no detrimental effect on patient self-reported QoL.